BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 11786909)

  • 1. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
    Shipp MA; Ross KN; Tamayo P; Weng AP; Kutok JL; Aguiar RC; Gaasenbeek M; Angelo M; Reich M; Pinkus GS; Ray TS; Koval MA; Last KW; Norton A; Lister TA; Mesirov J; Neuberg DS; Lander ES; Aster JC; Golub TR
    Nat Med; 2002 Jan; 8(1):68-74. PubMed ID: 11786909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
    Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
    Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving outcomes for patients with diffuse large B-cell lymphoma.
    Flowers CR; Sinha R; Vose JM
    CA Cancer J Clin; 2010; 60(6):393-408. PubMed ID: 21030533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
    Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic biomarkers in diffuse large B-cell lymphoma.
    Lossos IS; Morgensztern D
    J Clin Oncol; 2006 Feb; 24(6):995-1007. PubMed ID: 16418498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
    Møller MB; Christensen BE; Pedersen NT
    Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
    Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
    Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diagnosis of lymphoma: outcome prediction by gene expression profiling in diffuse large B-cell lymphoma.
    Last K; Debarnardi S; Lister TA
    Methods Mol Med; 2005; 115():15-63. PubMed ID: 15998962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of primary mediastinal large B-cell lymphomas].
    Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
    Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.